Vor Bio company information, Employees & Contact Information

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease Sahm

Vor Bio (NASDAQ: VOR) plans webcast on 48-week Phase 3 telitacicept data in Sjögren’s Stock Titan

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Yahoo Finance

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum Yahoo Finance

Vor Bio Shows 55% UPCR Reduction in Phase 3 IgAN Study | VOR Stock News Stock Titan

Vor Bio Announces Late-Breaking Oral Presentation of China GlobeNewswire

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer Yahoo Finance

76,360 Stock Options — Vor Bio Grants Options at $30.40 and RSUs to New Hires Stock Titan

Vor Bio Announces Late-Breaking Poster Presentation of GlobeNewswire

67.1% SRI‑4 response: Vor Bio's telitacicept vs 32.7% placebo in Phase 3 NEJM study Stock Titan

Vor Bio Announces Publication of China Phase 3 Study of GlobeNewswire

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors Yahoo Finance

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel Yahoo Finance

Vor Bio to Participate in Upcoming Investor Conferences GlobeNewswire

Vor Bio Announces Oral Presentation of 48-Week China Phase GlobeNewswire

7 Successful Drug Launches: Vor Bio Taps VYVGART Launch Veteran Navid Khan as Medical Affairs Chief Stock Titan

Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer GlobeNewswire

Clinical-Stage Biotech Vor Bio to Showcase Autoimmune Disease Pipeline at Stifel 2025 Virtual Forum Stock Titan

Clinical-Stage Biotech Vor Bio Sets Key Investor Presentations at Major September Healthcare Conferences Stock Titan

7 Million Stock Options: Vor Bio Awards Major Equity Package to New Biotech Talent Stock Titan

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer Yahoo Finance

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset GlobeNewswire

Vor Bio Announces $175 Million Private Placement GlobeNewswire

Major Autoimmune Breakthrough: Vor Bio's Phase 3 Sjögren's Disease Trial Results Set for ACR 2025 Reveal Stock Titan

Harvard Law Graduate Adi Osovsky Joins Clinical-Stage Biotech Vor Bio as General Counsel After iTeos Success Stock Titan

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer GlobeNewswire

Major Phase 3 Results: Vor Bio's Telitacicept Treatment for Generalized Myasthenia Gravis at AANEM Conference Stock Titan

Vor Bio Taps Commercial Powerhouse Behind Sarepta's $1.8B Revenue Surge for Global Drug Launch Stock Titan

PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement Business Wire

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value GlobeNewswire

Vor Bio Awards Massive 5.3M Share Package to New Development Chief: Full Grant Details Revealed Stock Titan

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer citybiz

$175M Mega-Deal: Vor Bio Lands Major Private Placement from RA Capital, Top Biotech Investors Stock Titan

Vor Bio's Massive $4B Autoimmune Drug Deal Transforms Company Under New CEO Leadership Stock Titan

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update GlobeNewswire

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors Yahoo Finance

Vor Bio Announces $55.6 Million Private Placement GlobeNewswire

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) The Manila Times

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design GlobeNewswire

Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update Yahoo Finance

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer Yahoo Finance

New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies GlobeNewswire

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Stock Titan

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference FinancialContent

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) FinancialContent

Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer citybiz